Crystal Research Associates has issued a 72-page Executive Informational Overview® (EIO) on life sciences technology company Tauriga Sciences, Inc. (TAUG-OTC). Tauriga is developing a portfolio of technologies believed to provide a clear and fast path to commercialization, which currently includes a synthetic biology platform and a natural wellness and medicinal cannabis business through the operations of subsidiaries Pilus Energy LLC and Honeywood LLC.

1. Crystal Research Associates Presents:
New Independent Equity Research
• New 72-page Executive Informational Overview® (EIO) by Crystal
Research Associates on Tauriga Sciences, Inc. (TAUG-OTC) is
available at www.crystalra.com
• Tauriga Sciences is a life sciences company focused on acquiring and
developing a portfolio of technologies which could provide a clear
and fast path to commercialization
o Pilus Energy LLC for the development of a wastewater-to-value
clean energy solution based on Bacterial Robotics’ microbial
technology
o Honeywood LLC for the development and commercialization of
of topical medicinal cannabis products
o Green Innovations Ltd. for the commercialization of bamboo-based,
.
hospital-grade paper products
o Bacterial Robotics LLC for development of a synthetic biology-based
wastewater remediation platform for the nuclear industry

2. What is an EIO?
• Crystal clear, comprehensive report on a company in a manner that is
easily understood by the Wall Street financial community
• Product/technology/service offerings, market size(s), key intellectual
property, leadership, growth strategy, competition, risks, financial
statements, key events, and other fundamental information are detailed
• Free of investment ratings, target prices, and forward-looking financial
.
models
• Complete risks and disclosures
• Written exclusively by experienced, award-winning analysts

3. Overview of Tauriga Sciences, Inc. (TAUG-OTC)
• Tauriga’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive
and non-exclusive basis, and entire businesses.
• The Company’s selection criteria for potential products, technologies, or businesses entails that they
.
meet the following:
1) a focus on innovation
2) a near-term revenue opportunity
3) a clear path to commercialization
4) large addressable markets
• Tauriga is focused on opportunities believed to have near-term revenue potential that do not require the
risky, lengthy, and costly clinical regulatory approval process normally associated with drug
development in the U.S.

4. Tauriga Sciences’ Summary of Assets
Acquisitions
Pilus Energy Honeywood LLC
Licensing
Green Innovations LTD Bacterial Robotics
.

5. Pilus Energy Subsidiary
• Wastewater-to-energy platform using genetically enhanced bacteria, called BactoBots™,
to clean pollutants from wastewater while generating electricity and valuable biogases
• BactoBots™ are used in conjunction with a scalable electrogenic bioreactor (EBR)—a microbial
fuel cell that harnesses abilities of bacteria while aiding in collection of economically important
byproducts
• Following initial proof of concept, Pilus Energy has announced a pilot study of its
wastewater-to-value technology on a commercial scale through a $1.7 million project with
the Metropolitan Sewer District of Greater Cincinnati (MSDGC), and is also pursuing a pilot
with large brewery and beverage manufacturer
• Tauriga eventually seeks to outlicense BactoBots™ manufacture to distributors and
.
customers worldwide
• The genetics rights management (GeRM™) platform needed to activate the BactoBots™
functions as anti-theft system as Tauriga retains control of GeRM™ creation and supply
• The global water industry is currently estimated to have a market value of $500 billion, and
is projected to reach $1 trillion by 2020

6. Honeywood Subsidiary and
“Cannabis Complements”
• Topical medicinal cannabis, which includes Doc Green’s Therapeutic Healing Cream,
shown below, (sold at >100 dispensaries in California), and “Vapura” Vapor Cartridge
• Able to manufacture medicinal cannabis products and high-grade medically sterile
cannabis extracts, and involved in licensing brands/delivery technologies as well as
supplying laboratory services infrastructure for fast-growing medical cannabis industry
• Medical marijuana industry is a new frontier in healthcare, as more patients seek out
natural remedies and safer alternatives to side effect-heavy prescription medicines
• Many medical users desire therapeutic effect of cannabis without the “high,” creating a
market for Honeywood’s topical, non-psychoactive (non-high-producing) products
.
The “Cannabis Complements” Product Line
• Tauriga’s natural wellness business also includes Cannabis Complements, a line of non-cannabis
dietary supplements and natural wellness products
• Tauriga’s first cannabis-free, natural supplement for appetite control, called Satietiva,
was recently launched in Colorado

7. Green Innovations Ltd.’s License
• On May 31, 2013, Tauriga executed a license agreement with Green Hygienics,
Inc. (GHI), a subsidiary of Green Innovations
• GHI is the North American distributor of American Hygienics Corporation’s 100%
tree-free, bamboo-based product line, which includes personal care and paper-based
.
goods
• GHI license agreement provides Tauriga with a five-year right to market and sell
an exclusive line of GHI’s products, including 100% tree-free, bamboo-based,
biodegradable, hospital-grade wipes as well as other similar products, in North
America
• Company plans to sell the products to commercial entities, including medical
facilities and schools

8. Bacterial Robotics LLC’s License
• Bacterial Robotics specializes in using synthetic biology to create unique bacterial “robots,” called
.
BactoBots™
• Microscopic bacteria-based organisms are engineered to conduct specific tasks as needed for the
water, energy, chemical, and pharmaceutical industries
• Tauriga’s strategic alliance with Bacterial Robotics refers to the class of BactoBots™ known as the
NuclearBot™ technology—a synthetic biology method for creating bacteria designed to cleanse the
wastewater generated through nuclear power plant operations
• JV is to market and sell products and services based on the NuclearBot™ technology as well as to
sublicense the NuclearBot™ intellectual property

9. Recently Achieved Milestones
• Entered into a strategic alliance agreement with Bacterial Robotics LLC for the creation of a joint
venture to develop and commercialize the NuclearBot™ technology
• Acquired Bacterial Robotics’ subsidiary Pilus Energy LLC, a developer of alternative wastewater-to-
.
value clean-tech energy solutions
• Initiated a $1.7 million pilot test of its Pilus Energy platform with the Metropolitan Sewer District
of Greater Cincinnati (MSDGC), and received EPA approval of the test
• Acquired California-based medicinal cannabis firm Honeywood LLC, a developer of a line of non-narcotic
topical medicinal cannabis products, and commenced development of Cannabis
Complements products
o Introduced its first product from the Cannabis Complements product line, Satietiva (a natural supplement for
appetite control), into the Colorado market
• Strengthened balance sheet by reducing in excess of $400,000 in convertible debt, and
performed multiple financing activities to fund acquisitions and operations
• Entered into an investment banking agreement with Dragoon Capital, Inc.

10. Potential Upcoming Milestones
.
• Begin Pilus Energy’s second pilot test
• Expand the Cannabis Complements product line
• Retire all remaining convertible debt
• Ramp-up revenues through the operations of its natural wellness businesses
(Honeywood and Tauriga’s Cannabis Complements product line) in order to up-list
its common shares to national stock exchange (e.g., NASDAQ or NYSE)

11. Management
• Stella M. Sung, Ph.D., Chairman and CEO—Almost 20 years experience as life
science VC and biotechnology executive; general partner/managing director
life science venture funds; led 7 venture rounds, co-founded 2 biotech
companies; served on 7 boards of directors and served as chairman of the
for 4 biotech companies; successful VC track record: chief business officer,
Cylene Pharmaceuticals, business development officer, Avita Medical (ASX:
and OTCQX: AVMXY); Harvard PhD in Chemistry under Professor Dudley
Herschbach (1986 Nobel Laureate)
• Seth M. Shaw, VP, Strategic Planning—Expertise in building companies and
capital raising; raised > $60 M in aggregate for several companies; founder,
Novastar Resources (now Lightbridge [NASDAQ: LTBR]), key relationships in
the nuclear power industry; founding CFO, Physician Therapeutics; Cornell
University degree
.

12. Management (cont.)
• Lawrence May, M.D., Chief Medical Officer—Board certified internist with
broad experience in clinical medicine, academics, media and business;
on the faculty of the UCLA medical school; previously Executive Vice President
for Medical and Scientific Affairs for Herbalife; undergraduate degree magna
cum laude in economics from Harvard University (’70), MD from Harvard
School (’74) and residency in internal medicine at Massachusetts General
Hospital.
.

13. To read the entire 72-page EIO on
Tauriga Sciences, Inc. (TAUG-OTC)
or find information on other companies under
coverage, please visit www.crystalra.com.
.

14. About Us
Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has
provided institutional-quality research on small- and mid-cap companies for the past decade.
We are led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the
international financial media for his years of work on Wall Street and for providing consistent
award-winning analyses and developing long-term relationships on both the buy-side and sell-side.
He has been consistently ranked among the Top Ten Analysts for pharmaceutical stock
performance in the world for almost two decades as well as ranked as the Number One Stock
Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally,
Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.
Corporate Headquarters:
880 Third Avenue, 6th Floor
New York, NY 10022
Office: (212) 851-6685
Fax: (609) 395-9339
Satellite Office Location:
2500 Quantum Lakes Drive, Suite 203
Boynton Beach, FL 33426
Office: (561) 542-6903
Fax: (561) 853-2246
.
Jeffrey J. Kraws,
Chief Executive Officer
Karen B. Goldfarb
President & COO

15. Connect with Crystal Research Associates
FACEBOOK — https://www.facebook.com/CrystalResearchAssociates
TWITTER — http://twitter.com/crystalresearch
YOUTUBE — https://www.youtube.com/user/crystalrsch
LINKEDIN — http://www.linkedin.com/company/crystal-research-associates
SLIDESHARE — http://www.slideshare.net/crystalresearchassociates
.